SmallCapStockAlert
2 weeks ago
FUNYMUNY - I lost millions of shares of PPCB in reverse splits just like you and all the rest of us. This is all part of the risk we investors take every day. A very large percentage of microcap stocks RS their shares just like PPCB did. That is what happened in the past for the company to stay alive. Investing in a stock is all about the future and what you think it is going to be. IM this is the first time PPCB is financing with bankers instead of toxic lenders. See the SI filings. This will advance the company to clinical trials where, if successful, (and previous trial was very promising), the share price could explode to very large numbers. There are very few shares out. PPCB has over 80 patents. PPCB has raised over $23 million. This upcoming funding should provide the money to complete a trial that if successful, the price will soar. I could be wrong, but I believe PPCB is positioned to surprise big on the upside.
RMS555
2 months ago
Did you notice how many shares were shown as being outstanding as of March 27, 2025 on the S-1/A? After the reverse split there was less than 16,000 shares outstanding! The total number of shares of Common Stock that will be outstanding after this offering is based on 11,611,781 shares of Common Stock outstanding as of March 27, 2025. Unless otherwise indicated, the shares outstanding after this offering assumes no exercise of outstanding options, warrants, or convertible notes and excludes the following:
? up to 250 shares of our Common Stock issuable upon exercise of Warrants to purchase Common Stock at an average exercise price of $600 (see โDescription of Our Securitiesโ for more information)
? 100,940 shares of our Common Stock issuance upon conversion of outstanding convertible notes
? 1,000,000 shares of our Common Stock issuable upon exercise of Warrants to purchase Common Stock pursuant to this offering (see โDescription of Our Securitiesโ for more information) (bold emphasis mine) https://www.otcmarkets.com/filing/html?id=18340584&guid=nPh-k6WMikASdth (bottom of page 4 after table of contents)
.